Angelman Syndrome Clinical Trial Pipeline Analysis: 20+ Key Companies Advancing the Future of Angelman Syndrome Therapeutics | DelveInsight

DelveInsight's Angelman Syndrome Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Angelman Syndrome therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are working to advance the Angelman Syndrome pipeline space and future growth potential of the Angelman Syndrome therapeutics market.

Key takeaways from the Angelman Syndrome Clinical Trial Landscape Report
• DelveInsight's Angelman Syndrome pipeline report depicts a developing therapeutic landscape with 20+ active companies working to develop therapies for Angelman Syndrome treatment.
• Key Angelman Syndrome companies such as Ultragenyx Pharmaceutical Inc., Roche, MavriX Bio, LLC, Encoded Therapeutics, Ionis Pharmaceuticals, Inc., Oak Hill Bio, and others are actively evaluating novel therapies for Angelman Syndrome.
• Promising Angelman Syndrome pipeline therapies in various stages of development include GTX-102, Alogabat, MVX-220, ETX 201, ION582, and others.

Request a sample and discover the recent advances in Angelman Syndrome treatment landscape. https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Angelman Syndrome?
Angelman syndrome is a rare neurodevelopmental disorder first described by British pediatrician Harry Angelman in 1965. It is characterized by intellectual disability, minimal or absent speech, ataxic movements, and a happy, social disposition. Angelman syndrome is commonly caused by loss of function of the maternally inherited UBE3A gene in the brain due to abnormalities in chromosome 15q11-13, leading to neurological and developmental impairments.
The syndrome is associated with severe developmental delays, seizures, movement and balance disorders, speech impairment, microcephaly, hyperactivity, sleep disturbances, gastrointestinal complications, and distinctive behavioral features including frequent smiling and laughter.
Diagnosis of Angelman syndrome is based on clinical evaluation, patient history, and genetic testing to identify deletions, mutations, imprinting defects, or uniparental disomy involving the UBE3A gene or chromosome 15q11-13 region.
Current management is primarily symptomatic and includes physiotherapy, occupational therapy, speech therapy, seizure management, nutritional support, and sleep management. Emerging therapies are focused on restoring or reactivating UBE3A gene expression.

Emerging Angelman Syndrome Drug Profiles
GTX-102: Ultragenyx Pharmaceutical Inc.
GTX-102 (apazunersen) is an investigational antisense oligonucleotide therapy administered intrathecally and designed to restore normal gene function in Angelman syndrome by targeting and inhibiting the UBE3A antisense transcript. By reactivating the paternal UBE3A allele, GTX-102 aims to restore UBE3A protein production, which is critical for neuronal and cognitive function. The therapy is currently in Phase III clinical development for Angelman Syndrome.
In June 2025, Ultragenyx Pharmaceutical Inc. announced that GTX-102 received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of Angelman syndrome. The therapy has also received Orphan Drug Designation, Rare Pediatric Disease Designation, Fast Track Designation, and PRIME designation.
MVX-220: MavriX Bio, LLC
MVX-220 is an investigational adeno-associated virus (AAV) gene therapy being developed by MavriX Bio, LLC for Angelman Syndrome. The therapy is administered through Intra-Cisterna Magna Injection and is currently in Phase I/II clinical development.
In September 2025, MavriX Bio announced that the US FDA granted Fast Track designation for MVX-220 for the treatment of Angelman syndrome. Earlier in May 2025, the company announced FDA clearance of its Investigational New Drug (IND) application for MVX-220.

Recent Developments in the Angelman Syndrome Clinical Trial Landscape
• In October 2025, Ultragenyx Pharmaceutical Inc. announced that the first patient had been dosed in the Aurora study evaluating the efficacy and safety of GTX-102 for Angelman syndrome.
• In July 2025, Ultragenyx Pharmaceutical Inc. announced that the Phase III Aspire study evaluating GTX-102 for Angelman Syndrome was fully enrolled with approximately 129 participants aged four to 17 years.
• In September 2025, Ionis Pharmaceuticals, Inc. announced that the US FDA granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome.
• In September 2025, MavriX Bio announced that the US FDA granted Fast Track designation for MVX-220, an investigational AAV gene therapy for Angelman syndrome.
• In April 2025, Oak Hill Bio entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824), an antisense oligonucleotide therapy designed for Angelman syndrome treatment.

Scope of the Angelman Syndrome Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intrathecal, Intravenous, Intra-Cisterna Magna Injection, Parenteral
• Therapeutics Assessment By Molecule Type: Antisense oligonucleotides, Small molecules, Gene therapies, Recombinant proteins
• Key Angelman Syndrome Companies: Ultragenyx Pharmaceutical Inc., Roche, MavriX Bio, LLC, Encoded Therapeutics, Ionis Pharmaceuticals, Inc., Oak Hill Bio, and others
• Key Angelman Syndrome Pipeline Therapies: GTX-102, Alogabat, MVX-220, ETX 201, ION582, and others

Dive deep into rich insights for new drugs for Angelman Syndrome treatment. https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Angelman Syndrome Pipeline Report Introduction
2. Angelman Syndrome Pipeline Report Executive Summary
3. Angelman Syndrome: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Angelman Syndrome Pipeline Therapeutics
6. Angelman Syndrome Pipeline: Late Stage Products (Phase III)
7. Angelman Syndrome Pipeline: Mid Stage Products (Phase II)
8. Angelman Syndrome Pipeline: Early Stage Products (Phase I/II)
9. Angelman Syndrome Pipeline: Preclinical and Discovery Stage Products
10. Angelman Syndrome Pipeline Therapeutics Assessment
11. Inactive Products in the Angelman Syndrome Pipeline
12. Company-University Collaborations (Licensing/Partnering/Funding) Analysis
13. Key Companies
14. Key Products in the Angelman Syndrome Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Angelman Syndrome pipeline therapeutics, reach out to DelveInsight. https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers market research reports, pipeline analysis, competitive intelligence, and forecasting solutions through its subscription-based platform PharmDelve.

This release was published on openPR.